Latest Financials News

Red Hill Minerals reports a profitable FY25 with robust royalty income from the Onslow Iron Project, declaring a fully franked final dividend of 6.5 cents per share.

Resimac Group has successfully settled a A$1 billion non-conforming residential mortgage backed securities transaction, marking its second such bond issuance this year. The deal attracted strong domestic and offshore investor interest, reinforcing Resimac’s diversified funding strategy.

GR Engineering Services Limited has updated its dividend details for the first half of FY2025, declaring a fully franked dividend of 12 cents per share and setting the Dividend Reinvestment Plan price at AUD 3.897 with a 2.5% discount.

Challenger Limited has announced the Dividend Reinvestment Plan (DRP) issue price for its final 2025 dividend at $8.3615 per share, with a modest 2% participation rate leading to the issuance of approximately 266,000 new shares.

Xamble Group Limited has successfully closed a partially underwritten rights issue, raising approximately A$1.36 million to accelerate its digital marketing platform expansion in Southeast Asia.

Andromeda Metals' latest Scoping Study reveals a compelling economic case for its innovative High Purity Alumina (HPA) production technology, highlighting strong returns and a significant carbon emissions advantage. The project aims to meet soaring global demand with a 10,000 tonne per annum facility in South Australia.

Resolution Minerals Ltd has successfully raised $25.1 million through a heavily supported placement, positioning itself to advance its Horse Heaven Project in Idaho and prepare for a NASDAQ listing.

Blue Star Helium Limited reports steady progress on its Galactica helium project in Colorado, with first helium production on track for December 2025 and full ramp-up expected through 2026.

Western Gold Resources has completed over 45% of its 35,300-metre grade control and infill drilling program at the Gold Duke Project, receiving initial assay results from the Eagle prospect. The company is finalizing an updated scoping study and secured $3 million in non-dilutive funding to support a planned mining start in late 2025.

Neurizon Therapeutics has locked in a significant R&D tax incentive advance covering overseas and domestic development costs for its lead ALS drug candidate NUZ-001, accelerating its clinical progress with a $5.6 million rebate expected in 2025.

Neurizon Therapeutics has raised $5 million through an institutional placement to advance its lead ALS drug candidate NUZ-001 into a pivotal clinical trial, pending FDA clearance. The capital injection also supports manufacturing and pre-clinical development efforts.

Mont Royal Resources Ltd (ASX – MRZ) has lodged a prospectus to raise between A$8 million and A$10 million through a share offer priced at A$0.20 each, coinciding with a proposed merger with Commerce Resources Corp (TSXV – CCE). The combined entity aims to become a leading Quebec-focused critical minerals developer.